Patents Examined by Jane Zara
  • Synthetic lariat RNA for RNA interference
    Patent number: 9546364
    Abstract: Provided herein are compositions for the modification of gene expression by RNA interference using a microRNA (miRNA) guide strand precursor. Methods of making and using the miRNA guide strand precursor also are provided. The compositions bypass the Drosha-Exportin-Dicer pathway and are resistant to nucleases.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: January 17, 2017
    Assignee: Carnegie Mellon University
    Inventors: Subha Ranjan Das, Eduardo Paredes
  • Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
    Patent number: 9540651
    Abstract: The invention provides novel immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit or suppress TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen.
    Type: Grant
    Filed: July 6, 2015
    Date of Patent: January 10, 2017
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Ekambar R. Kandimalla, Daqing Wang, Ireneusz Nowak, Sudhir Agrawal
  • MIR-193A-3P and associated genes predict tumorigenesis and chemotherapy outcomes
    Patent number: 9540698
    Abstract: The disclosure provides a correlation between the expression level of the miR-193a gene, which can be regulated by its methylation status, and both tumorigenesis of and the resistance of a cancer cell to a pyrimidine antimetabolite (5-FU) based chemotherapy. In addition to the methylation status and the expression of miR-193a, its downstream genes, such as E2F1, SRSF2, and apoptotic genes such as caspase 2, are also involved and can serve as useful markers for cancer therapy prognosis and for therapy selection.
    Type: Grant
    Filed: July 23, 2015
    Date of Patent: January 10, 2017
    Assignee: Genedia Biotech Co., Ltd.
    Inventor: Jingde Zhu
  • Antisense antibacterial method and compound
    Patent number: 9534220
    Abstract: A method and antisense compound for inhibiting the growth of pathogenic bacterial cells are disclosed. The compound contains no more than 12 nucleotide bases and has a targeting nucleic acid sequence of no fewer than 10 bases in length that is complementary to a target sequence containing or within 10 bases, in a downstream direction, of the translational start codon of a bacterial mRNA that encodes a bacterial protein essential for bacterial replication. The compound binds to a target mRNA with a Tm of between 50° to 60° C. The relatively short antisense compounds are substantially more active than conventional antisense compounds having a targeting base sequence of 15 or more bases.
    Type: Grant
    Filed: November 19, 2012
    Date of Patent: January 3, 2017
    Assignee: Sarepta Therapeutics, Inc.
    Inventors: Bruce L. Geller, Jesse D. Deere, Patrick L. Iversen
  • Individualized cancer therapy
    Patent number: 9528991
    Abstract: In certain embodiments, the invention provides methods for treating cancer, comprising: obtaining a specimen of cancer tissue and normal tissue from a patient; extracting total protein; obtaining a protein expression profile; identifying over-expressed proteins; comparing the protein expression profile to a gene expression profile; identifying at least one prioritized protein target; designing a first RNA interference expression cassette; designing a first RNA interference expression cassette to modulate the expression of at least one gene encoding; incorporating the first cassette into a delivery vehicle; and providing a patient with an effective amount of the first delivery vehicle.
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: December 27, 2016
    Assignee: GRADALIS, INC.
    Inventors: David M. Shanahan, John J. Nemunaitis, I, Neil Senzer, Phillip B. Maples, Donald Rao
  • Sorafenib-microRNA combination therapy for liver cancer
    Patent number: 9517245
    Abstract: A method of treating a subject having liver cancer can include administering a synthetic oligonucleotide to a subject having liver cancer, the oligonucleotide comprising a sequence that is at least 80% identical to at least one of SEQ ID NO:1-12 (e.g., a miR-34 or miR-215 mimic); and administering sorafenib to the subject, wherein the molar ratio of sorafenib:oligonucleotide administered to the subject is in the range of about 10-2000 (e.g., a ratio that provides a superior, for example synergistic or greater than additive, effect).
    Type: Grant
    Filed: February 27, 2015
    Date of Patent: December 13, 2016
    Assignee: MIRNA THERAPEUTICS, INC.
    Inventors: Andreas Bader, Jane Zhao
  • Isoform-selective inhibitors and activators of PDE3 cyclic nucleotide phosphodiesterases
    Patent number: 9513289
    Abstract: The present invention concerns methods and compositions related to type 3 phosphodiesterases (PDE3). Certain embodiments concern isolated peptides corresponding to various PDE3A isoforms and/or site-specific mutants of PDE3A isoforms, along with expression vectors encoding such isoforms or mutants. In specific embodiments, methods for identifying isoform-selective inhibitors or activators of PDE3 are provided, along with methods of use of such inhibitors or activators in the treatment of dilated cardiomyopathy, pulmonary hypertension and/or other medical conditions related to PDE3 effects on cAMP levels in different intracellular compartments.
    Type: Grant
    Filed: March 27, 2014
    Date of Patent: December 6, 2016
    Assignees: The United Sates of America, as Represented by the Department of Veterans Affairs, University of Utah Research Foundation
    Inventor: Matthew A. Movsesian
  • Isoform-selective inhibitors and activators of PDE3 cyclic nucleotide phosphodiesterases
    Patent number: 9513288
    Abstract: The present invention concerns methods and compositions related to type 3 phosphodiesterases (PDE3). Certain embodiments concern isolated peptides corresponding to various PDE3A isoforms and/or site-specific mutants of PDE3A isoforms, along with expression vectors encoding such isoforms or mutants. In specific embodiments, methods for identifying isoform-selective inhibitors or activators of PDE3 are provided, along with methods of use of such inhibitors or activators in the treatment of dilated cardiomyopathy, pulmonary hypertension and/or other medical conditions related to PDE3 effects on cAMP levels in different intracellular compartments.
    Type: Grant
    Filed: November 14, 2013
    Date of Patent: December 6, 2016
    Assignees: The United States of America as Represented by the Department of Veterans Affairs, University of Utah Research Foundation
    Inventor: Matthew A. Movsesian
  • Methods for treating denervation-induced muscle atrophy
    Patent number: 9511057
    Abstract: The present invention provides methods for the treatment of denervation-induced skeletal muscle atrophy, and generally, denervation-induced skeletal muscle degeneration diseases using agents that decrease the activity of mammalian target of rapamycin and/or the activity of at least one of the Forkhead Box Transcription Factors 1, 3 and 4.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: December 6, 2016
    Assignee: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
    Inventors: Huibin Tang, Joseph Shrager
  • Modifications for antisense compounds
    Patent number: 9506059
    Abstract: The invention pertains to modifications for antisense oligonucleotides, wherein the modifications are used to improve stability and provide protection from nuclease degradation. The modifications could also be incorporated into double-stranded nucleic acids, such as synthetic siRNAs and miRNAs.
    Type: Grant
    Filed: September 26, 2014
    Date of Patent: November 29, 2016
    Assignee: Integrated DNA Technologies, Inc.
    Inventors: Mark Aaron Behlke, Richard Owczarzy, Yong You, Joseph Alan Walder, Kim Lennox
  • Modifications for antisense compounds
    Patent number: 9506057
    Abstract: The invention pertains to modifications for antisense oligonucleotides, wherein the modifications are used to improve stability and provide protection from nuclease degradation. The modifications could also be incorporated into double-stranded nucleic acids, such as synthetic siRNAs and miRNAs.
    Type: Grant
    Filed: February 25, 2013
    Date of Patent: November 29, 2016
    Assignee: Integrated DNA Technologies, Inc.
    Inventors: Mark Aaron Behlke, Kimberly Ann Lennox, Ashley Mae Jacobi, Richard Owczarzy, Joseph Alan Walder
  • Methods of eliminating or reducing expression of genes in filamentous fungal strains by transitive RNA interference
    Patent number: 9499820
    Abstract: The present invention relates to methods of reducing or eliminating expression of a target gene in a filamentous fungal strain by transitive RNA interference.
    Type: Grant
    Filed: December 20, 2007
    Date of Patent: November 22, 2016
    Assignee: NOVOZYMES, INC.
    Inventors: Howard Brody, Donna Moyer, Amanda Fisher
  • Antisense compounds targeting genes associated with fibronectin
    Patent number: 9487780
    Abstract: Provided are compounds comprising oligonucleotides complementary to a fibronectin transcript. Certain such compounds are useful for hybridizing to a fibronectin transcript, including but not limited to a fibronectin transcript in a cell. Such hybridization results in modulation of splicing of the fibronectin transcript. Such compounds are used to treat one or more symptoms associated with fibrosis. Such compounds are used to treat one or more symptoms associated with renal fibrosis.
    Type: Grant
    Filed: June 3, 2013
    Date of Patent: November 8, 2016
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Susan M. Freier, Frank Rigo, Mark Dockrell, Felicia Heidibrecht
  • Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase
    Patent number: 9487809
    Abstract: The present invention provides methods and compositions for reducing lactate production and increasing polypeptide production in cultured cells. In one aspect, the invention provides a method comprising culturing cells expressing a) a small interfering RNA (siRNA) specific for a lactate dehydrogenase (LDH) and b) an siRNA specific for a pyruvate dehydrogenase kinase (PDHK). In another aspect, the invention provides cultured cells or vectors comprising an siRNA specific for a LDH and an siRNA specific for a PDHK.
    Type: Grant
    Filed: November 28, 2012
    Date of Patent: November 8, 2016
    Assignee: Genentech, Inc.
    Inventors: Meixia Zhou, Bradley Richard Snedecor, Chi Kin Domingos Ng, Amy Shen
  • Antisense antibacterial method and compound
    Patent number: 9487784
    Abstract: A method and antisense compound for inhibiting the growth of pathogenic bacterial cells are disclosed. The compound contains no more than 12 nucleotide bases and has a targeting nucleic acid sequence of no fewer than 10 bases in length that is complementary to a target sequence containing or within 10 bases, in a downstream direction, of the translational start codon of a bacterial mRNA that encodes a bacterial protein essential for bacterial replication. The compound binds to a target mRNA with a Tm of between 50° to 60° C. The relatively short antisense compounds are substantially more active than conventional antisense compounds having a targeting base sequence of 15 or more bases.
    Type: Grant
    Filed: November 19, 2012
    Date of Patent: November 8, 2016
    Assignee: Sarepta Therapeutics, Inc.
    Inventors: Bruce L. Geller, Jesse D. Deere, Patrick L. Iversen
  • Methods and compositions for the diagnosis, classification, and treatment of cancer
    Patent number: 9458456
    Abstract: Some embodiments of the present technology relate to methods and compositions for the diagnosis and treatment of cancer. Some embodiments include methods and compositions for the diagnosis and treatment of castration-resistant prostate cancer. Some embodiments include methods and compositions for the diagnosis and treatment of pancreatic cancer.
    Type: Grant
    Filed: March 30, 2012
    Date of Patent: October 4, 2016
    Assignee: UNIVERSITY OF SOUTH ALABAMA
    Inventors: Ajay Pratap Singh, Sanjeev Srivastava, Seema Singh
  • Methods for enhancing utrophin production via inhibition of microRNA
    Patent number: 9458459
    Abstract: This invention provides a method for enhancing utrophin protein production in a cell by inhibiting an utrophin microRNA molecule. Moreover, the invention provides that methods for enhancing utrophin protein production in a muscle cell are used for treating a muscular dystrophy and/or other myopathies.
    Type: Grant
    Filed: November 19, 2014
    Date of Patent: October 4, 2016
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Catherine Moorwood, Utpal Basu, Gopal Patel, Olga Lozynska, Tejvir S. Khurana
  • Detection and destruction of cancer cells using programmed genetic vectors
    Patent number: 9458472
    Abstract: In its various embodiments, the invention provides, first, a composition comprising a vector for transfecting a cell. The vector comprises a first nucleic acid encoding an antisense agent having thereon an RNA interference target for a transcript of a gene endogenous to the cell. The vector further comprises a second nucleic acid that encodes a cell-killing agent. The second nucleic acid further comprises a sequence of nucleotides transcribable into a non-coding region of a transcript of the second nucleic acid, such that the non-coding region becomes an RNA interference target for the antisense agent. In the transfected cell, the vector operates to interfere with the expression of the cell-killing agent unless and until the vector senses certain endogenous gene signals, whereupon it releases the cell-killing agent.
    Type: Grant
    Filed: October 15, 2009
    Date of Patent: October 4, 2016
    Assignee: Massachusetts Institute of Technology
    Inventors: Ron Weiss, Priscilla E. M. Purnick, Caroline DeHart, Jon Monk, Aparna Swaminathan
  • Microrna profiling for diagnosis of dysplastic nevi and melanoma
    Patent number: 9447471
    Abstract: Provided herein are methods for miRNA profiling for the diagnosis, prognosis, and management of melanoma and differentiation of melanoma from nevi.
    Type: Grant
    Filed: December 27, 2012
    Date of Patent: September 20, 2016
    Assignee: QUEST DIAGNOSTICS INVESTMENTS INCORPORATED
    Inventors: Kevin Qu, Anthony Sferruzza, Ke Zhang, Yan Liu, Renius Owen
  • MiRNA for treating diseases and conditions associated with neo-angiogenesis
    Patent number: 9441222
    Abstract: The invention relates to the diagnostic and therapeutic uses of a miRNA molecule, an equivalent or a source thereof in a disease and condition associated with neo-angiogenesis.
    Type: Grant
    Filed: July 2, 2013
    Date of Patent: September 13, 2016
    Assignee: INTERNA TECHNOLOGIES B.V.
    Inventors: Sanne Weijzen, Roeland Quirinus Jozef Schaapveld, Meriem Bourajjaj, Rick Jan Van Haastert, Arjan Willem Griffioen, Judith Rosina Van Biejnum, Edwin Pieter Johan Gerard Cuppen, Eugene Berezikov, Andreas Alphons Franciscus Ludovicus Van Piujenbroek, Willemijn Maria Gommans, Negar Babae, Petronella Innocentia Van Noort